Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 176 entries
Sorted by: Best Match Show Resources per page
Literature evidence in open targets - a target validation platform.

Journal of biomedical semantics

Kafkas Ş, Dunham I, McEntyre J.
PMID: 28587637
J Biomed Semantics. 2017 Jun 06;8(1):20. doi: 10.1186/s13326-017-0131-3.

BACKGROUND: We present the Europe PMC literature component of Open Targets - a target validation platform that integrates various evidence to aid drug target identification and validation. The component identifies target-disease associations in documents and ranks the documents based...

Cite
Kafkas Ş, Dunham I, McEntyre J. Literature evidence in open targets - a target validation platform. J Biomed Semantics. 2017;8(1):20doi: 10.1186/s13326-017-0131-3.
Kafkas, �. �., Dunham, I., & McEntyre, J. (2017). Literature evidence in open targets - a target validation platform. Journal of biomedical semantics, 8(1), 20. https://doi.org/10.1186/s13326-017-0131-3
Kafkas, Şenay, et al. "Literature evidence in open targets - a target validation platform." Journal of biomedical semantics vol. 8,1 (2017): 20. doi: https://doi.org/10.1186/s13326-017-0131-3
Kafkas Ş, Dunham I, McEntyre J. Literature evidence in open targets - a target validation platform. J Biomed Semantics. 2017 Jun 06;8(1):20. doi: 10.1186/s13326-017-0131-3. PMID: 28587637; PMCID: PMC5461726.
Copy Download .nbib Format: NLM
[Why do we need molecular medicine in oncology].

Revue medicale suisse

Hofer S.
PMID: 26939185
Rev Med Suisse. 2016 Jan 27;12(503):210-1.

No abstract available.

Cite
Hofer S. Weshalb wir die molekulare Medizin in der Onkologie brauchen. [Why do we need molecular medicine in oncology]. Rev Med Suisse. 2016;12(503):210-1
Hofer, S. (2016). Weshalb wir die molekulare Medizin in der Onkologie brauchen. [Why do we need molecular medicine in oncology]. Revue medicale suisse, 12(503), 210-1.
Hofer, Silvia. "Weshalb wir die molekulare Medizin in der Onkologie brauchen." [Why do we need molecular medicine in oncology]. Revue medicale suisse vol. 12,503 (2016): 210-1.
Hofer S. Weshalb wir die molekulare Medizin in der Onkologie brauchen. [Why do we need molecular medicine in oncology]. Rev Med Suisse. 2016 Jan 27;12(503):210-1. German. PMID: 26939185.
Copy Download .nbib Format: NLM
Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN

Agarwal R, Wang J, Wilson K, Barrett W, Morris JC.
PMID: 27697975
J Natl Compr Canc Netw. 2016 Oct;14(10):1203-1207. doi: 10.6004/jnccn.2016.0130.

Anaplastic thyroid cancer (ATC) is an aggressive uncommon malignancy with limited treatment. Traditional antineoplastic chemotherapy has not been successful in the management of metastatic ATC. As a result, the focus has shifted to the development of novel therapies for...

Cite
Agarwal R, Wang J, Wilson K, et al. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. J Natl Compr Canc Netw. 2016;14(10):1203-1207doi: 10.6004/jnccn.2016.0130.
Agarwal, R., Wang, J., Wilson, K., Barrett, W., & Morris, J. C. (2016). Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 14(10), 1203-1207. https://doi.org/10.6004/jnccn.2016.0130
Agarwal, Rishi, et al. "Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer." Journal of the National Comprehensive Cancer Network : JNCCN vol. 14,10 (2016): 1203-1207. doi: https://doi.org/10.6004/jnccn.2016.0130
Agarwal R, Wang J, Wilson K, Barrett W, Morris JC. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. J Natl Compr Canc Netw. 2016 Oct;14(10):1203-1207. doi: 10.6004/jnccn.2016.0130. PMID: 27697975.
Copy Download .nbib Format: NLM
Targeted Therapies in Pediatric Oncology.

Drug research

Fischer M.
PMID: 30453366
Drug Res (Stuttg). 2018 Nov;68:S14. doi: 10.1055/a-0733-0816. Epub 2018 Nov 19.

No abstract available.

Cite
Fischer M. Targeted Therapies in Pediatric Oncology. Drug Res (Stuttg). 2018;68:S14doi: 10.1055/a-0733-0816.
Fischer, M. (2018). Targeted Therapies in Pediatric Oncology. Drug research, 68S14. https://doi.org/10.1055/a-0733-0816
Fischer, Matthias. "Targeted Therapies in Pediatric Oncology." Drug research vol. 68 (2018): S14. doi: https://doi.org/10.1055/a-0733-0816
Fischer M. Targeted Therapies in Pediatric Oncology. Drug Res (Stuttg). 2018 Nov;68:S14. doi: 10.1055/a-0733-0816. Epub 2018 Nov 19. PMID: 30453366.
Copy Download .nbib Format: NLM
Matching up.

Nature medicine

Chakradhar S.
PMID: 29988140
Nat Med. 2018 Jul;24(7):882-884. doi: 10.1038/s41591-018-0113-8.

No abstract available.

Cite
Chakradhar S. Matching up. Nat Med. 2018;24(7):882-884doi: 10.1038/s41591-018-0113-8.
Chakradhar, S. (2018). Matching up. Nature medicine, 24(7), 882-884. https://doi.org/10.1038/s41591-018-0113-8
Chakradhar, Shraddha. "Matching up." Nature medicine vol. 24,7 (2018): 882-884. doi: https://doi.org/10.1038/s41591-018-0113-8
Chakradhar S. Matching up. Nat Med. 2018 Jul;24(7):882-884. doi: 10.1038/s41591-018-0113-8. PMID: 29988140.
Copy Download .nbib Format: NLM
Visualizing Cancer.

Cancer cell

Krummel M, Hu K, de Vries EGE, Goetz JG, Passaro D, Subramaniam S, Misteli T, Skala M, Bravo-Cordero JJ, Sutcliffe JL.
PMID: 33321083
Cancer Cell. 2020 Dec 14;38(6):753-756. doi: 10.1016/j.ccell.2020.11.014.

Imaging has had a profound impact on our ability to understand and treat cancer. We invited some experts to discuss imaging approaches that can be used in various aspects of cancer research, from investigating the complexity and diversity of...

Cite
Krummel M, Hu K, de Vries EGE, et al. Visualizing Cancer. Cancer Cell. 2020;38(6):753-756doi: 10.1016/j.ccell.2020.11.014.
Krummel, M., Hu, K., de Vries, E. G. E., Goetz, J. G., Passaro, D., Subramaniam, S., Misteli, T., Skala, M., Bravo-Cordero, J. J., & Sutcliffe, J. L. (2020). Visualizing Cancer. Cancer cell, 38(6), 753-756. https://doi.org/10.1016/j.ccell.2020.11.014
Krummel, Matthew, et al. "Visualizing Cancer." Cancer cell vol. 38,6 (2020): 753-756. doi: https://doi.org/10.1016/j.ccell.2020.11.014
Krummel M, Hu K, de Vries EGE, Goetz JG, Passaro D, Subramaniam S, Misteli T, Skala M, Bravo-Cordero JJ, Sutcliffe JL. Visualizing Cancer. Cancer Cell. 2020 Dec 14;38(6):753-756. doi: 10.1016/j.ccell.2020.11.014. PMID: 33321083.
Copy Download .nbib Format: NLM
Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ramsey SD, Shankaran V, Sullivan SD.
PMID: 31233352
J Clin Oncol. 2019 Dec 20;37(36):3472-3474. doi: 10.1200/JCO.18.02320. Epub 2019 Jun 24.

No abstract available.

Cite
Ramsey SD, Shankaran V, Sullivan SD. Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources. J Clin Oncol. 2019;37(36):3472-3474doi: 10.1200/JCO.18.02320.
Ramsey, S. D., Shankaran, V., & Sullivan, S. D. (2019). Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(36), 3472-3474. https://doi.org/10.1200/JCO.18.02320
Ramsey, Scott D, et al. "Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources." Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 37,36 (2019): 3472-3474. doi: https://doi.org/10.1200/JCO.18.02320
Ramsey SD, Shankaran V, Sullivan SD. Basket Cases: How Real-World Testing for Drugs Approved Based on Basket Trials Might Lead to False Diagnoses, Patient Risks, and Squandered Resources. J Clin Oncol. 2019 Dec 20;37(36):3472-3474. doi: 10.1200/JCO.18.02320. Epub 2019 Jun 24. PMID: 31233352.
Copy Download .nbib Format: NLM
The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.

Cell

Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R.
PMID: 31951522
Cell. 2020 Jan 09;180(1):9-14. doi: 10.1016/j.cell.2019.12.009.

This commentary introduces a new clinical trial construct, the Master Observational Trial (MOT), which hybridizes the power of molecularly based master interventional protocols with the breadth of real-world data. The MOT provides a clinical venue to allow molecular medicine...

Cite
Dickson D, Johnson J, Bergan R, et al. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020;180(1):9-14doi: 10.1016/j.cell.2019.12.009.
Dickson, D., Johnson, J., Bergan, R., Owens, R., Subbiah, V., & Kurzrock, R. (2020). The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell, 180(1), 9-14. https://doi.org/10.1016/j.cell.2019.12.009
Dickson, Dane, et al. "The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine." Cell vol. 180,1 (2020): 9-14. doi: https://doi.org/10.1016/j.cell.2019.12.009
Dickson D, Johnson J, Bergan R, Owens R, Subbiah V, Kurzrock R. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell. 2020 Jan 09;180(1):9-14. doi: 10.1016/j.cell.2019.12.009. PMID: 31951522.
Copy Download .nbib Format: NLM
An industry perspective on drug target validation.

Expert opinion on drug discovery

Jones LH.
PMID: 27111834
Expert Opin Drug Discov. 2016 Jul;11(7):623-5. doi: 10.1080/17460441.2016.1182484. Epub 2016 May 09.

No abstract available.

Cite
Jones LH. An industry perspective on drug target validation. Expert Opin Drug Discov. 2016;11(7):623-5doi: 10.1080/17460441.2016.1182484.
Jones, L. H. (2016). An industry perspective on drug target validation. Expert opinion on drug discovery, 11(7), 623-5. https://doi.org/10.1080/17460441.2016.1182484
Jones, Lyn H. "An industry perspective on drug target validation." Expert opinion on drug discovery vol. 11,7 (2016): 623-5. doi: https://doi.org/10.1080/17460441.2016.1182484
Jones LH. An industry perspective on drug target validation. Expert Opin Drug Discov. 2016 Jul;11(7):623-5. doi: 10.1080/17460441.2016.1182484. Epub 2016 May 09. PMID: 27111834.
Copy Download .nbib Format: NLM
Precision Medicine 2030.

Clinical pharmacology and therapeutics

Pacanowski M, Liu Q.
PMID: 31782136
Clin Pharmacol Ther. 2020 Jan;107(1):62-64. doi: 10.1002/cpt.1675. Epub 2019 Nov 28.

No abstract available.

Cite
Pacanowski M, Liu Q. Precision Medicine 2030. Clin Pharmacol Ther. 2019;107(1):62-64doi: 10.1002/cpt.1675.
Pacanowski, M., & Liu, Q. (2020). Precision Medicine 2030. Clinical pharmacology and therapeutics, 107(1), 62-64. https://doi.org/10.1002/cpt.1675
Pacanowski, Michael, and Liu, Qi. "Precision Medicine 2030." Clinical pharmacology and therapeutics vol. 107,1 (2020): 62-64. doi: https://doi.org/10.1002/cpt.1675
Pacanowski M, Liu Q. Precision Medicine 2030. Clin Pharmacol Ther. 2020 Jan;107(1):62-64. doi: 10.1002/cpt.1675. Epub 2019 Nov 28. PMID: 31782136.
Copy Download .nbib Format: NLM
The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.

Biochimie

Muralidar S, Ambi SV, Sekaran S, Krishnan UM.
PMID: 32971147
Biochimie. 2020 Dec;179:85-100. doi: 10.1016/j.biochi.2020.09.018. Epub 2020 Sep 22.

An acute respiratory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that surfaced in China in late 2019, continues to spread rapidly across the globe causing serious concerns. The coronavirus disease 2019 (COVID-19) is declared as...

Cite
Muralidar S, Ambi SV, Sekaran S, et al. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85-100doi: 10.1016/j.biochi.2020.09.018.
Muralidar, S., Ambi, S. V., Sekaran, S., & Krishnan, U. M. (2020). The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie, 17985-100. https://doi.org/10.1016/j.biochi.2020.09.018
Muralidar, Shibi, et al. "The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2." Biochimie vol. 179 (2020): 85-100. doi: https://doi.org/10.1016/j.biochi.2020.09.018
Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020 Dec;179:85-100. doi: 10.1016/j.biochi.2020.09.018. Epub 2020 Sep 22. PMID: 32971147; PMCID: PMC7505773.
Copy Download .nbib Format: NLM
Mining the Microbiome for Drug Targets.

Methods in enzymology

Wang Q, Yang F, Jia H.
PMID: 30390805
Methods Enzymol. 2018;610:59-72. doi: 10.1016/bs.mie.2018.09.014. Epub 2018 Oct 25.

The human microbiome is our "other genome." Implicated in a growing list of complex diseases, for which genomic studies typically explain a portion of the disease susceptibility, the human gut microbiome has been at the spotlight for our understanding...

Cite
Wang Q, Yang F, Jia H. Mining the Microbiome for Drug Targets. Methods Enzymol. 2018;610:59-72doi: 10.1016/bs.mie.2018.09.014.
Wang, Q., Yang, F., & Jia, H. (2018). Mining the Microbiome for Drug Targets. Methods in enzymology, 61059-72. https://doi.org/10.1016/bs.mie.2018.09.014
Wang, Qi, et al. "Mining the Microbiome for Drug Targets." Methods in enzymology vol. 610 (2018): 59-72. doi: https://doi.org/10.1016/bs.mie.2018.09.014
Wang Q, Yang F, Jia H. Mining the Microbiome for Drug Targets. Methods Enzymol. 2018;610:59-72. doi: 10.1016/bs.mie.2018.09.014. Epub 2018 Oct 25. PMID: 30390805.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 176 entries